{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 28,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a combination of a treatment matrix and a donut chart to align product labeling with real-world patient needs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/10",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Donut chart showing 84% mixed episodes, 13% manic episodes, and 3% other.",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14f93d07-9e36-4c2c-a205-a0c8f3a90a45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.02,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4a407f-4445-4947-a03d-cbb052c31ccf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Healthcare providers (n=172) surveyed reported that majority of their bipolar I disorder patients faced mixed episodes (manic and depressive symptoms)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64df792e-0343-4943-87dc-5965dd1af5e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Survey question: What Bipolar I disorder symptoms is this patient facing, that you hope to treat with their current therapy regimen? Source: Alkermes Market Survey; Fielded April 29 to June 2, 2022; N=172 HCPs (515 Patient Charts)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2024fcfb-6a41-431c-bb9b-f3701502effa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.02,
        "y": 0.375
      },
      "kind": "table",
      "text": "Treatment matrix showing LYBALVI indications for manic, mixed, and maintenance episodes as monotherapy or adjunct therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae866b4e-6261-4cfd-bba4-9d3d369bd8b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "LYBALVI®: Bipolar I Disorder Label Relevant to Real-World Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aee29271-9eba-4b4d-b563-c0d4419dedff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "b5e82a75-9d1e-42f1-ad64-c2ddbcacf5a8",
      "evidence": "Treatment matrix showing LYBALVI indications for manic, mixed, and maintenance episodes as monotherapy or adjunct therapy",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "6d35d34e-b7cc-496c-bea5-417850fd8b1c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents LYBALVI as a solution with strong launch traction.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "03ac4acb-09ea-4723-97d7-19dbedfde939",
      "evidence": "The deck presents LYBALVI's prescription growth trends and market sizing.",
      "position": 0,
      "objective": "What are the key features and benefits of LYBALVI?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}